×
ASH News Daily
http://www.hematology.org/Annual-Meeting/AND.aspx

Nov 7th, 2018 - ASH News Daily is the official print publication of the ASH annual meeting. View an archive of recent ASH News Daily publications

ASH 2018 coming attractions look at the big picture
https://www.mdedge.com/hematologynews/article/189383/aggressive-lymphomas/ash-2018-coming-attractions-look-big-picture

Nov 21st, 2018 - Big trials, big results in malignant and nonmalignant hematologic disorders are on the program at the 2018 ASH annual meeting.

What's Hot at This Year's ASH Meeting?
https://www.medscape.com/viewarticle/905521

Nov 23rd, 2018 - The premier event in hematology is celebrating its diamond anniversary. This will be the 60th annual meeting of the American Society of Hematology (ASH). It will be returning to the city of San Diego, California, and will run from November 30 to December 4.

Every Patient Tells a Story: Using Narrative Medicine to Cure Disease
https://www.ashclinicalnews.org/on-location/every-patient-tells-story-using-narrative-medicine-cure-disease/

Nov 21st, 2018 - As part of the Education Program at the 2018 ASH annual meeting, three physician-writers will offer their take on the intersection of storytelling, writing, and medicine – asking why doctors should care about the narrative, how the patient narrative informs treatment decisions, and how writing can be a tool for advocacy and change.

ASH-a-Palooza: Trainee Day. Reimagined
https://www.ashclinicalnews.org/on-location/ash-palooza-trainee-day-reimagined/

Nov 21st, 2018 - The “Trainee Day” that attendees may know from past annual meetings has been reimagined as ASH-a-Palooza – a new educational experience that will offer a relaxed, open learning environment for trainees in a festival-like setting with multiple opportunities for micro-learning. During breaks between sessions at Petco Park, trainees can enjoy ballpark-style food and are invited to visit informatio...

For the Love of the Lab: Interview with John E. Dick, PhD
https://www.ashclinicalnews.org/on-location/love-lab-interview-john-e-dick-phd/

Nov 21st, 2018 - John E. Dick, PhD, recipient of the 2018 Mentor Award in basic science, tells us about his career in the lab – from working at “the mecca of stem-cell research” to learning how to foster creativity in his own lab

Platelet Biogenesis in the Lung Circulation
http://www.bloodjournal.org/content/132/Suppl_1/SCI-22

Nov 21st, 2018 - Platelets are indispensable in hemostasis, thrombosis, and immune responses. In humans, billions of platelets are produced each day from megakaryocytes, however the mechanisms of mature platelet production are incompletely understood. Megakaryocytes are produced in the bone marrow and have been visualized to communicate with the bone marrow sinusoids to release proplatelet fragments. Megakaryoc...

Overall Survival of HIV-Positive Patients with HLH
http://www.bloodjournal.org/content/132/Suppl_1/4957

Nov 21st, 2018 - Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening disorder affecting the interplay between natural killer cells, macrophages, and cytotoxic lymphocytes. In HLH, persistent macrophage activation results from dysregulated cytokines produced from T-lymphocytes. The disease can be primary (due to a genetic defect) or secondary (triggered by another disease proces...

Hemophagocytic Lymphohistiocytosis in Early Infancy- Pitfall of Differentiation between Hereditary and Infectious Reasons
http://www.bloodjournal.org/content/132/Suppl_1/4961

Nov 21st, 2018 - Hemophagocytic Lymphohistiocytosis (HLH) is characterized by pathologic immune activation which occurs either as a familial disorder or as an acquired condition. The diagnosis of HLH requires the presence of five out of nine criteria: fever, splenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis in bone marrow, hyperferritinemia, low or absent natural killer cell...

IL-6 As a Potential Cell Released Marker of Prostate Cancer Cell Death
http://www.bloodjournal.org/content/132/Suppl_1/4964

Nov 21st, 2018 - Introduction: Interleukin 6 (IL-6) is proinflammatory cytokine which is produced by cell when Nod-like receptors (NLRs) are activated. Increased production of IL-6 was shown to promote tumor growth and metastasis.Therefore, it could be suggested that activation of NLRs could support malignancy. PC-3, prostate tumor derived cells, was shown to produce IL-6; however, little is known about the rol...

5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis
http://www.bloodjournal.org/content/132/Suppl_1/2644

Nov 21st, 2018 - Acute myeloid leukemia (AML) is a clonal hematologic malignancy characterized by genomic heterogeneity and epigenetic changes, including aberrant DNA hypermethylation. Phase-Ib clinical data in relapsed/refractory AML patients indicate that combining venetoclax with the hypomethylating agents (HMAs) 5-azacitidine (5-Aza) or decitabine results in an overall response (OR) of 62% (DiNardo et al. 2...

A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy
http://www.bloodjournal.org/content/132/Suppl_1/1502

Nov 21st, 2018 - Introduction Chemotherapy induced clonal selection and development are major contributors to disease relapse and resistance to therapy in AML. An immediate response to chemotherapy in intracellular signalling networks can be detected within minutes in vivo. (Irish J. et al 2004) We hypothesize that by analyzing the immediate intracellular chemotherapy response we might reveal which cancer clone...

A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia
http://www.bloodjournal.org/content/132/Suppl_1/277

Nov 21st, 2018 - Introduction: Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has recently demonstrated high success but also shown limitations regarding their toxicity and development of CD19negative variants. Here we reported results from a phase I study designed to determine the safety of the CD19 CAR-T and CD22 CAR-T cocktail and the feasibility of making enough quantities to treat patients w...

A Genome-Wide CRISPR Screen Implicates MYC Dysregulation in TCF3-PBX1 B-ALL
http://www.bloodjournal.org/content/132/Suppl_1/3915

Nov 21st, 2018 - Introduction: Acute lymphoblastic leukaemia (ALL) is the most common paediatric cancer, of which, precursor B-cell ALL (B-ALL) accounts for approximately 80% of diagnoses. B-ALL is a heterogeneous disease, with patients characterised and risk stratified according to their cytogenetic profile. TCF3-PBX1 B-ALL was associated with a poor prognosis, but on current therapies outcome has greatly impr...

A Long-Term Retrospective Analysis of Arsenic-Containing Triple-Agents Treatment for Acute Promyelocytic Leukemia (APL) in a Cohort from a Single Hospital
http://www.bloodjournal.org/content/132/Suppl_1/4060

Nov 21st, 2018 - Objective: The long-term efficacy (June 2001 - May 2018) of newly diagnosed APL patients (pts) treated with either As4S4 or As2O3 in combination of all-trans retinoid acid (ATRA), and anthracycline-based chemotherapy in Lu Dao-Pei Hospital is analyzed. Methods: Firstly, 8 years from June 2001 to December 2009, a total of 88 newly diagnosed with APL patients were divided into two groups, who wer...

A Network Meta-Analysis of Clinical Trials Assessing Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Among Young Adults
http://www.bloodjournal.org/content/132/Suppl_1/1432

Nov 21st, 2018 - Introduction: After establishing the diagnosis of acute myeloid leukemia (AML), remission induction chemotherapy is started with curative intent. Due to paucity of direct therapeutic comparison of induction regimens, relative efficacy of two drug standard regimens and three drug induction regimens among newly diagnosed young (<60 years) AML patients is not established. We conducted a systematic...

A Novel Predictor of Response to Gemtuzumab Ozogamicin Therapy in AML Provides Strategies for Sensitization of Leukemia Stem Cells in Individual Patients
http://www.bloodjournal.org/content/132/Suppl_1/2765

Nov 21st, 2018 - Acute myeloid leukemia (AML) patients with normal cytogenetics, NPM1 mutation, and no FLT3-ITD are considered to be at low molecular risk (LMR). We previously reported that most LMR patients have a low LSC17 score; these patients derive benefit from the addition of low fractionated doses of gemtuzumab ozogamicin (GO) to standard treatment and have favorable survival outcomes compared to patient...

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CL...
http://www.bloodjournal.org/content/132/Suppl_1/1849

Nov 21st, 2018 - Introduction: Chronic Lymphocytic Leukemia (CLL) is frequently accompanied by immune dysregulation. Hypogammaglobulinemia is one of the most important immune defects encountered, and all three classes of immunoglobulins (IgG, A and M) can be involved. Recently, novel heavy+light chain (HLC) immunoassays have become available that quantify the light chain types of each immunoglobulin class (e.g....

A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose
http://www.bloodjournal.org/content/132/Suppl_1/1457

Nov 21st, 2018 - Background: Older patients (pts) with AML unfit for intense induction chemotherapy have a poor prognosis with a 5 year survival of <10%. 225Ac-lintuzumab is composed of 225Ac linked to a humanized anti-CD33 monoclonal antibody. Data were previously presented on the initial 13 pts who received 2.0 µCi/kg/dose on Days 1 and 8 (ASH, 2017, Abstract 616). Although that dose resulted in a high respon...

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute M...
http://www.bloodjournal.org/content/132/Suppl_1/27

Nov 21st, 2018 - INTRODUCTION: Overexpression of CD123, the alpha subunit of the IL-3 receptor, in multiple hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and blastic plasmacytoid dendritic cell neoplasm (BPDCN), makes this antigen an attractive target for the development of new therapeutics. IMGN632 is a CD123-targeting antibody-drug conjugate comprising...